CSBR · Champions Oncology, Inc.
Champions Oncology Inc (CSBR)
What's happening
- CSBR is up 2.15% today, trading at $4.99. — Live quote
- Volume today (506) is well below its 3-month average of 9,000. (Finnhub fundamentals)
- Reports earnings on 2026-09-16, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.05 actual vs. $-0.05 estimated (+2.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-07-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jan '26 | Oct '25 | Jul '25 | Jan '25 | Oct '24 |
|---|---|---|---|---|---|
| Market cap | $101.9M | $90.7M | $95.8M | $157.9M | $56.6M |
| P/E | 25.17 | 17.95 | 15.71 | 39.42 | -22.12 |
| Price/Sales | 1.63 | 1.52 | 1.64 | 2.79 | 1.11 |
| Price/Book | 23.79 | 21.75 | 27.32 | 28.87 | 83.17 |
| EV/Revenue | 1.51 | 1.38 | 1.46 | 2.73 | 1.05 |
| EV/EBITDA | 17.77 | 12.84 | 11.20 | — | — |
| ROE | 94.51% | 121.22% | 173.89% | 73.25% | -375.92% |
| ROA | 14.23% | 16.76% | 19.97% | 13.08% | -10.14% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 12.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-K, filed 2026-07-27; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -1.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -27.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CSBR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jan '26 | Oct '25 | Jul '25 | Jan '25 | Oct '24 | Jul '24 | Jan '24 | Oct '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6M | $15.0M | $14.0M | $17.0M | $13.5M | $14.1M | $12.0M | $11.6M |
| Operating income | -$276.0K | $185.0K | -$527.0K | $4.5M | $732.0K | $1.3M | -$2.6M | -$2.0M |
| Net income | -$279.0K | $268.0K | -$436.0K | $4.5M | $728.0K | $1.3M | -$2.5M | -$2.1M |
| EPS (diluted) | $-0.02 | $0.02 | $-0.03 | $0.31 | $0.05 | $0.09 | $-0.19 | $-0.15 |
| EPS (basic) | $-0.02 | $0.02 | $-0.03 | $0.33 | $0.05 | $0.10 | $-0.19 | $-0.15 |
| Operating margin | -$2 | $1 | -$4 | $26 | $5 | $9 | -$21 | -$17 |
| Net margin | -$2 | $2 | -$3 | $26 | $5 | $9 | -$21 | -$18 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $27.0M | $28.4M | $30.2M | $30.5M | $32.3M | $30.6M | $25.2M | $24.9M |
| Total liabilities | $22.9M | $24.1M | $25.9M | $27.0M | $28.6M | $25.2M | $24.6M | $25.3M |
| Stockholders' equity | $3.9M | $4.3M | $4.2M | $3.5M | $3.8M | $5.5M | $681.0K | -$332.0K |
| Total current assets | $19.2M | $20.2M | $21.3M | $21.0M | $22.4M | $19.7M | $14.1M | $13.2M |
| Total current liabilities | $19.9M | $20.7M | $22.1M | $22.7M | $23.9M | $19.9M | $18.9M | $19.2M |
| Cash & equivalents | — | $7.1M | $8.5M | $10.3M | $9.8M | $3.2M | $2.8M | $2.9M |
| Accounts receivable | $13.2M | $12.1M | $11.5M | $9.5M | $11.2M | $15.8M | $10.5M | $9.0M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K |
| Other non-current assets | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K |
| Accounts payable | $6.9M | $5.7M | $6.0M | $4.8M | $4.2M | $5.1M | $4.9M | $5.2M |
| Accrued liabilities | $2.6M | $3.3M | $2.2M | $1.8M | $2.6M | $2.3M | $2.2M | $2.1M |
| Deferred revenue (current) | $8.8M | $10.0M | $12.3M | $14.4M | $15.4M | $10.9M | $10.2M | $10.3M |
| Other current liabilities | $79.0K | $78.0K | $97.0K | $116.0K | $135.0K | $154.0K | $151.0K | $151.0K |
| Other non-current liabilities | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K |
| Common stock & paid-in capital | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K |
| Retained earnings | -$81.1M | -$80.4M | -$80.1M | -$80.4M | -$79.9M | -$78.1M | -$82.6M | -$83.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.0M | -$1.3M | -$1.7M | $600.0K | $6.9M | $490.0K | -$283.0K | $311.0K |
| Investing cash flow | -$238.0K | -$14.0K | -$242.0K | -$46.0K | -$253.0K | -$42.0K | -$94.0K | $0 |
| Financing cash flow | -$19.0K | -$36.0K | $168.0K | -$14.0K | -$32.0K | $0 | $239.0K | -$37.0K |
| Free cash flow | -$2.2M | -$1.4M | -$2.0M | $554.0K | $6.6M | $448.0K | -$377.0K | $311.0K |
| Capital expenditures | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 |
| Depreciation & amortization | $1.0M | $341.0K | $357.0K | $358.0K | $1.2M | $398.0K | $399.0K | $449.0K |
| Share-based compensation | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K |
| Deferred income taxes | $0 | — | — | — | $0 | — | — | — |
| Change in accounts receivable | $1.2M | $498.0K | $2.1M | -$1.8M | -$4.5M | $5.3M | $1.2M | -$565.0K |
| Change in accounts payable | $1.3M | -$437.0K | $1.3M | $411.0K | -$614.0K | -$188.0K | -$382.0K | -$565.0K |
| Share repurchases | — | — | — | — | $0 | $0 | $0 | $0 |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 |
|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M |
| Operating income | -$1.1M | $4.6M | -$7.4M | -$5.3M | $607.0K |
| Net income | -$1.2M | $4.7M | -$7.3M | -$5.3M | $548.0K |
| EPS (diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
| EPS (basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 |
| Operating margin | -$2 | $8 | -$15 | -$10 | $1 |
| Net margin | -$2 | $8 | -$15 | -$10 | $1 |
Balance sheet
| Line item | Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 |
|---|---|---|---|---|---|
| Total assets | $27.0M | $32.3M | $26.1M | $34.3M | $35.4M |
| Total liabilities | $22.9M | $28.6M | $28.0M | $29.7M | $26.3M |
| Stockholders' equity | $3.9M | $3.8M | -$1.9M | $4.6M | $9.1M |
| Total current assets | $19.2M | $22.4M | $13.6M | $19.5M | $19.7M |
| Total current liabilities | $19.9M | $23.9M | $21.5M | $21.7M | $17.5M |
| Cash & equivalents | — | — | — | — | — |
| Accounts receivable | $13.2M | $11.2M | $9.5M | $8.0M | $9.5M |
| Property, plant & equipment | — | — | — | — | — |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K |
| Other non-current assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K |
| Accounts payable | $6.9M | $4.2M | $5.8M | $5.3M | $2.9M |
| Accrued liabilities | $2.6M | $2.6M | $2.2M | $2.3M | $2.4M |
| Deferred revenue (current) | $8.8M | $15.4M | $12.1M | $12.8M | $11.1M |
| Other current liabilities | $79.0K | $135.0K | $150.0K | $145.0K | — |
| Other non-current liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K |
| Common stock & paid-in capital | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K |
| Retained earnings | -$81.1M | -$79.9M | -$84.6M | -$77.3M | -$72.0M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Apr '26 | Apr '25 | Apr '24 | Apr '23 | Apr '22 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | $7.4M | -$6.1M | $4.0M | $6.5M |
| Investing cash flow | -$540.0K | -$389.0K | -$836.0K | -$2.9M | -$2.4M |
| Financing cash flow | $99.0K | $170.0K | -$527.0K | $11.0K | $207.0K |
| Free cash flow | -$5.0M | $7.0M | -$7.0M | $1.1M | $4.1M |
| Capital expenditures | $564.0K | $389.0K | $836.0K | $2.9M | $2.4M |
| Depreciation & amortization | $1.4M | $1.6M | $1.9M | $2.1M | $1.5M |
| Share-based compensation | $1.2M | $654.0K | $1.1M | $864.0K | $912.0K |
| Deferred income taxes | $0 | $0 | — | — | — |
| Change in accounts receivable | $2.0M | $1.4M | $2.0M | -$1.3M | $2.8M |
| Change in accounts payable | $2.6M | -$1.7M | $465.0K | $2.5M | $974.0K |
| Share repurchases | — | $0 | $634.0K | $74.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CSBR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-10-17 to 2025-10-30
Recent transactions
- Most recent: ACKERMAN JOEL (Director) — Option exercise of 94,405 shares on 2025-10-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| ACKERMAN JOEL | Director | Option exercise | 2025-10-30 | 94,405 |
| Breitfeld Philip P. | Director | Other acquisition/disposition | 2025-03-25 | 4,150 |
| Mendelson Daniel Newman | Director | Open market purchase | 2024-01-12 | 1,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-10-30 | ACKERMAN JOEL | Director | Option exercise | 94,405 | $2.10 |
| 2025-03-25 | Breitfeld Philip P. | Director | Other acquisition/disposition | 4,150 | $0.00 |
| 2024-10-31 | ACKERMAN JOEL | Director | Option exercise | 88,470 | $2.10 |
| 2024-10-31 | ACKERMAN JOEL | Director | Option exercise | 16,667 | $5.43 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:58 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-07-27 | 10-K | 2026-04-30 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-03-30 | 8-K | 2026-03-24 | View on SEC.gov → |
| 2026-03-12 | 10-Q | 2026-01-31 | View on SEC.gov → |
| 2026-03-12 | 8-K | 2026-03-12 | View on SEC.gov → |
| 2026-01-30 | 4 | 2025-07-16 | View on SEC.gov → |
| 2026-01-30 | 4 | 2021-11-05 | View on SEC.gov → |
| 2025-12-15 | 10-Q | 2025-10-31 | View on SEC.gov → |
| 2025-12-15 | 8-K | 2025-12-15 | View on SEC.gov → |
| 2025-11-07 | 4 | 2025-11-05 | View on SEC.gov → |
| 2025-11-07 | 4 | 2025-11-05 | View on SEC.gov → |
| 2025-11-07 | 4 | 2025-11-05 | View on SEC.gov → |
Recent news
Headlines about CSBR (Champions Oncology, Inc.). Links open the publisher — we don’t host full articles.
-
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging
Yahoo Finance · 2026-09-01 -
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Yahoo Finance · 2026-07-30 -
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...
Yahoo Finance · 2026-07-30 -
Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA
Seeking Alpha · 2026-07-27 -
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Seeking Alpha · 2026-07-27 -
Champions Oncology Q4 Earnings Call Highlights
Yahoo Finance · 2026-07-27 -
Champions Oncology Reports Record Annual Revenue of $59 Million
Yahoo Finance · 2026-07-27 -
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Yahoo Finance · 2026-07-23
No headlines in this category right now — try “All”.